Testing donor-like immune T cells for children with liver cancer
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have one of these diagnoses: hepatoblastoma, HCN-NOS, or hepatocellular carcinoma, confirmed by pathology (biopsy/surgery results).
- Your blood test shows AFP greater than 100, and this is measured around the time of screening, especially after the most recent standard treatment line.
- The cancer has either returned after initial standard treatment (relapsed) or did not respond to standard treatment (refractory).
- Age is 1 to 21 years, and the treatment team estimates you may have more than 4 months to live.
- Tumor size checks matter: for one part of the study you need at least one lesion ≥5 mm, or two or more lesions ≥3 mm (for the other part, tumors must be measurable on scans).
- You need certain immune genetics: you must have at least one HLA-A2 type, and liver health must be Child-Pugh A6 or better.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This trial tests a new treatment using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It is for people whose cancer has progressed after at least two standard treatments and who have tumors that can be biopsied to grow these cells.
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
This Phase 3 study tests a modified treatment plan for children newly diagnosed with hepatoblastoma, a type of liver cancer. It may help improve how well treatment works and how safely it can be given by using a structured approach.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This Phase 2 study tests an immune-cell treatment (activated T lymphocytes) given after your liver cancer tumor has been fully removed. It aims to improve safety and reduce the chance of the cancer coming back in people with early-stage hepatocellular carcinoma.
Hear when a new Hepatoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.